Source link : https://www.newshealth.biz/health-news/tpoxx-no-better-than-placebo-for-clade-i-mpox/
The antiviral drug tecovirimat (Tpoxx) failed to shorten the duration of mpox lesions or lower mortality among children and adults with clade I mpox in the Democratic Republic of the Congo (DRC), according to results from the randomized, placebo-controlled PALM007 trial. Among hospitalized patients with mpox, lesion resolution took a median of 7 days with […]
Author : News Health
Publish date : 2024-10-18 18:50:19
Copyright for syndicated content belongs to the linked Source.